MatriceLAB Innove

What MatriceLAB Innove does

MatriceLAB Innove is a privately held French diagnostic laboratory founded in 2012 and headquartered in Créteil (94000), operating in the reproductive medicine space. The company offers the UTIMPRO test, a CE-marked in vitro diagnostic medical device that profiles the endometrial immune environment through biomarker analysis of biopsy tissue collected during the implantation window. The test targets women with repeated IVF/ICSI implantation failures or unexplained recurrent miscarriages, identifying immune dysregulation in 81.5% of a clinical cohort of 1,811 women. Clinical evidence cited from randomized prospective PHRC studies (Lédée et al. 2016, 2020, 2025, 2026) indicates a 40–50% relative increase in expected birth rates at first embryo transfer after treatment application, and pregnancy rates of 51% versus 39.9% in patients using the company's therapeutic control biopsy (bilan sous thérapeutique).

The business model is built on a physician-mediated distribution channel: gynecologists and reproductive medicine specialists order test kits via the company's website, perform endometrial biopsies in-clinic, and mail samples to MatriceLAB's Créteil laboratory, which returns analysis results to both the patient (by post) and the prescribing physician (with therapeutic recommendations) within approximately three weeks. Pricing is entirely out-of-pocket — the initial test is priced at €416 and the follow-up therapeutic assessment at €300, both reduced in 2024 from prior levels to expand access ahead of planned national reimbursement. The biopsy procedure itself is covered by French Social Security under the AMP pathway, but MatriceLAB's analysis fee is not. The company is pursuing inclusion in the RIHN (référentiel innovant des actes hors nomenclature) with the Haute Autorité de Santé, targeted for 2027, which would represent a material inflection point for demand by converting the offering from self-pay to reimbursed.

With 1–10 employees, founder ownership (Dr. Nathalie Ledee and Marie Petitbarat as co-founders), no disclosed external funding, and €10,000 share capital, MatriceLAB operates as a lean, research-driven micro-entity. Its commercial reach today is regional (France-focused) with stated intent to expand internationally and to develop additional diagnostic tests in the broader women's reproductive immunology space. Revenue is not publicly disclosed.

Name

MatriceLAB Innove

Legal name

MatriceLAB Innove SAS

Website

https://matricelabinnove.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

MatriceLAB Innove is a French diagnostic laboratory offering the CE-marked UTIMPRO test, an immunological biomarker analysis of endometrial tissue to identify causes of repeated IVF implantation failure and recurrent miscarriage in women, with results delivered to physicians for personalized treatment planning.

Ownership category

akta.pro rank

Product category

Reproductive Immunology Diagnostics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Immunoassay Diagnostics (ELISA, chemiluminescence, serology) (HLAAALAB)

Keywords

• Endometrial receptivity testing
• Immunological diagnostic services
• Reproductive immunology testing
• IVF failure diagnostics
• Recurrent miscarriage testing

Headquarters

HQ city

Créteil

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

1. UTIMPRO Diagnostic Test (Bilan initial): Patients/couples pay out-of-pocket for the immunological analysis of their endometrial biopsy. The biopsy procedure itself is covered by French Social Security (100% coverage under AMP pathway), but the MatriceLab analysis fee is not reimbursed. The initial test is priced at €416 as of 2024. The company targets women with repeated IVF failures or recurrent unexplained miscarriages, a self-pay niche within the fertility treatment market. Prices were reduced from prior levels to improve accessibility while awaiting national reimbursement via RIHN (planned for 2027).
2. Therapeutic Control Biopsy Analysis (Bilan sous thérapeutique): A follow-up diagnostic test performed after the patient has undergone the initially prescribed treatment, to verify its effectiveness before the next embryo transfer attempt. This second analysis allows treatment adaptation if insufficient efficacy is detected. Priced at €300 (reduced from €416), representing a 30% reduction to improve patient access. This creates a recurring diagnostic revenue opportunity linked to each patient's treatment cycle.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

MatriceLAB Innove operates a medical diagnostic laboratory that performs immunological analysis of endometrial biopsies to identify uterine immune dysregulation in women experiencing repeated IVF/ICSI implantation failures or recurrent miscarriages. The core offering is the UTIMPRO test, a CE-marked in vitro diagnostic medical device that profiles endometrial biomarkers during the implantation window and proposes personalized therapeutic strategies to improve embryo implantation success. The laboratory also offers a follow-up therapeutic control biopsy to verify treatment efficacy before the next embryo transfer.

Product overview

MatriceLAB Innove offers a single unified diagnostic product centered on the MatriceLab (UTIMPRO) immunological test. This test analyzes endometrial biomarkers to establish a uterine immune receptivity profile and proposes personalized therapeutic strategies for women experiencing implantation failure or recurrent miscarriages. The company also provides an optional therapeutic assessment test (bilan sous thérapeutique) as a follow-up module to evaluate treatment efficacy, and a sample collection kit (Kit MatriceLab) containing all necessary materials for endometrial biopsy.

Differentiator

Problem solved

Functional benefit

Brands

• UTIMPRO test: The MatriceLab immunological test for endometrial receptivity, a CE-marked in vitro diagnostic medical device that analyzes biomarkers to determine uterine immune balance and propose therapeutic strategies.

Products and services

• Test MatriceLab (UTIMPRO test)
• Bilan sous thérapeutique (Therapeutic assessment test)

Quantifiable outcome

• 40–50% relative increase in expected birth rates at first embryo transfer after treatment application following the MatriceLab test (Lédée et al. 2025, Frontiers)
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Quest Diagnostics: Quest Diagnostics operates a national medical laboratory network with reproductive and women's health testing services, including immunology assays. While not offering a direct equivalent to UTIMPRO, it competes as a broad-scale diagnostic lab with potential to expand into specialized reproductive immunology.
• CooperSurgical: CooperSurgical acquired Igenomix and offers ERA, EMMA, and ALICE endometrial diagnostics alongside a broad fertility and women's health portfolio. Competes with MatriceLab in the reproductive diagnostics space with vastly greater commercial reach and resources.
• Vitrolife: Vitrolife is a global IVF solutions provider that owns Igenomix and offers the ERA endometrial receptivity test. Competes with MatriceLab in endometrial diagnostics and operates a broader portfolio of IVF media, consumables, and genetic services.

Direct peers

• Igenomix (Vitrolife): Igenomix offers the ERA (Endometrial Receptivity Analysis) test for endometrial receptivity, the most direct global competitor to MatriceLab's UTIMPRO. Both target IVF patients with implantation failure using endometrial biopsy diagnostics, though Igenomix uses transcriptomics while MatriceLab uses immunological biomarkers.

Peers

• Laboratory Corporation of America (Labcorp):

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/MatriceLab
• LinkedInlinkedin.com/company/matricelab-innove
• Instagraminstagram.com/matricelab_innove

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MatriceLAB Innove